GEP20043233B - Composition Containing Blocking Monoclonal Antibody VLA-1 - Google Patents

Composition Containing Blocking Monoclonal Antibody VLA-1

Info

Publication number
GEP20043233B
GEP20043233B GEAP20006273A GEAP2000006273A GEP20043233B GE P20043233 B GEP20043233 B GE P20043233B GE AP20006273 A GEAP20006273 A GE AP20006273A GE AP2000006273 A GEAP2000006273 A GE AP2000006273A GE P20043233 B GEP20043233 B GE P20043233B
Authority
GE
Georgia
Prior art keywords
monoclonal antibody
composition containing
blocking monoclonal
containing blocking
vla
Prior art date
Application number
GEAP20006273A
Inventor
Koteliansky, (Us) Victor
Philip Gotwals
Lobb, (Us) Roy
Fougerolles Antonin De (Ca)
Original Assignee
Biogen Inc Us
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc Us filed Critical Biogen Inc Us
Publication of GEP20043233B publication Critical patent/GEP20043233B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C07K2316/96—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

1. Technical Result Increase in treatment of inflammatory disorders, particularly the treatment of arthritis. 2. Essence A composition is disclosed blocking antibody which is capable of binding an epitope of VLA-1 3. Field of Application Medicine.
GEAP20006273A 1999-06-01 2000-06-01 Composition Containing Blocking Monoclonal Antibody VLA-1 GEP20043233B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18533699P 1999-06-01 1999-06-01
US13703899P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
GEP20043233B true GEP20043233B (en) 2004-05-25

Family

ID=82020314

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20006273A GEP20043233B (en) 1999-06-01 2000-06-01 Composition Containing Blocking Monoclonal Antibody VLA-1

Country Status (1)

Country Link
GE (1) GEP20043233B (en)

Similar Documents

Publication Publication Date Title
IL103981A (en) CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
EP0880597A4 (en) THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8
DE69433406D1 (en) ANTIBODIES AGAINST CD40
EP1476120A4 (en) Treatment methods using anti-cd22 antibodies
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
NZ568769A (en) Human monoclonal antibodies against CD20
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
NZ239617A (en) Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant
HK1154352A1 (en) A blocking monoclonal antibody to the human alpha1 i-domain of vla-1, and its use for the treatment of inflammatory disorders 1 i- vla-1
SE8605295D0 (en) MONOCLONAL ANTIBODIES CROSS-REACTIVE AND CROSSPROTECTIVE AGAINST P. AERUGINOSA SEROTYPES
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
WO2003026692A3 (en) Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
DE3889062D1 (en) Monoclonal antibody against human BCDF.
ITRM920457A0 (en) MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF THE HUMAN P-GLYCOPROTEIN.
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
AU2712192A (en) Monoclonal antibodies against mycoplasma pneumoniae, hybridomas producing these, methods for the preparation thereof, and the use thereof
BG102667A (en) Diosgenine-containing composition
GEP20043233B (en) Composition Containing Blocking Monoclonal Antibody VLA-1
DE606516T1 (en) Against human ceruloplasmin monoclonal antibody.
GB2257830B (en) Low output-capacity, double-diffused field effect transistor
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
NO974852L (en) Human <beta> 2-integrin <alfa> subunit
TW223019B (en)
EP0640621A3 (en) Anti-thrombin monoclonal antibody.